Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose crossover study of formoterol/mometasone MDI with or without spacer in children with persistent asthma
2014-004582-24Phase 2
- Sponsor
- Merck & Co.
- Start
- Apr 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of mometasone and formoterol in persistent asthma (5 arms), sponsored by Merck & Co. Primary endpoint: Area under the curve from 0 to 12 hours of the change from baseline in FEV1.
02
Drugs
mometasoneformoterol
03
Conditions
persistent asthma
Beyond the preview
Go deeper on 2014-004582-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004582-24.